Cytogen Cuts 75 Percent of AxCell Biosciences’ Staff
AxCell Biosciences said last week it had laid off three out of four employees and suspended “certain projects” as its parent, Cytogen, tries to cut costs and focus more on its core R&D. Cytogen said AxCell will continue to develop its signal-transduction pathway database for clinical research and functional proteomics.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
